Why Armata Is Rising In Pre-market?

January 13, 2026 — 07:40 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Armata Pharmaceuticals (ARMP) announced the conclusion of an End-of-Phase 2 written response from the FDA and plans to advance the company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The Phase 3 study is anticipated to initiate in the second half of 2026.

FDA's Center for Biologics Evaluation and Research division confirmed that the safety and efficacy data from Armata's Phase 2a diSArm study support advancement to Phase 3. Also, the FDA provided critical guidance on key elements of the Phase 3 study design. The company noted that the FDA included recommendations for the future Biologics License Application and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation for AP-SA02.

In pre-market trading on NYSE American, Armata Pharmaceuticals shares are up 5.9 percent to $7.01.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Why Armata Is Rising In Pre-market?

Tags

Latest Articles